Greg Berk, MD

Chief Medical Officer

Dr. Greg Berk serves as senior clinical advisor to Vigeo. His previous experience includes serving as chief medical officer for Verastem Oncology; president, chief medical officer, and board member of Sideris Pharmaceuticals; chief medical officer of BIND Therapeutics; chief medical officer of Intellikine, Inc., now part of Takeda Oncology; and senior vice president of global clinical development for Abraxis BioScience.

Dr. Berk has served as an investigator on several industry-sponsored and cooperative group oncology trials, including the pivotal studies of Gleevec® and Avastin®. In addition, he has been a faculty member of Weill Cornell Medical College and New York-Presbyterian Hospital, where he also completed his internship, residency, and fellowship in internal medicine, hematology, and oncology. He earned his medical degree from Case Western Reserve University.